Optic Nerve Disorders Treatment Market Report 2026

Optic Nerve Disorders Treatment Market Overview

• Optic Nerve Disorders Treatment market size has reached to $3.98 billion in 2025 • Expected to grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Impact Of Rising Prevalence Of Eye Disorders On The Optic Nerve Disorder Treatment Market • Market Trend: First Generic Version of Prednisolone Acetate For Optic Nerve Disorders • North America was the largest region in 2025.

What Is Covered Under Optic Nerve Disorders Treatment Market?

Optic nerve disorder treatment refers to the medical interventions and approaches aimed at diagnosing, managing and potentially improving or preserving the function of the optic nerve, which is responsible for transmitting visual information from the eye to the brain. This treatment is used to cure the condition where the patterns of visual loss are brought on by inherited or acquired abnormalities of the optic nerves. The main types of optic nerve disorders treatment are immunomodulators therapy, steroidal therapy and others. Immunomodulator therapy refers to treatment using medications that raise or decrease your immune response, allowing the immune system to function more efficiently. The various indications include glaucoma, optic neuritis, optic neuropathy, congenital optic atrophy and others. These are used by various end-users such as hospitals, ambulatory surgery centers, clinics and others.

What Is The Optic Nerve Disorders Treatment Market Growth Forecast?

The optic nerve disorders treatment market size is expected to see strong growth in the next few years. It will grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising clinical research in neuroprotection therapies, increasing adoption of immunomodulators and biologics, growing awareness of inherited optic nerve disorders, expansion of specialized ophthalmic care centers, increasing demand for personalized treatment protocols. Major trends in the forecast period include rising focus on early diagnosis and intervention for optic nerve damage, increasing adoption of combination therapies for inflammatory and degenerative optic disorders, growing emphasis on long-term disease management and vision preservation, rising demand for neuroprotective and supportive treatment approaches, increasing integration of multidisciplinary care in optic nerve disorder treatment.

Global Optic Nerve Disorders Treatment Market Segmentation

1) By Treatment Type: Steroidal Therapy, Immunomodulators therapy, Other Treatment Types 2) By Indication: Glaucoma, Optic Neuritis, Optic Neuropathy, Congenital Optic Atrophy, Other Indications 3) By End User: Hospitals, Ambulatory Surgery Centers, Clinics, Other End Users Subsegments: 1) By Steroidal Therapy: Corticosteroids, Intravitreal Steroid Injections, Oral Steroids 2) By Immunomodulators Therapy: Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Agents, Intravenous Immunoglobulin (IVIG) 3) By Other Treatment Types: Optical Nerve Decompression Surgery, Neuroprotective Agents, Supportive Therapies

What Is The Driver Of The Optic Nerve Disorders Treatment Market?

The increase in the prevalence of eye disorders is expected to propel the growth of the optic nerve disorder treatment market going forward. Eye disorders refer to illnesses or conditions that affect the eyes' tissues and other components. Optic nerve disorder treatment helps patients suffering from eye disorders treating various eye ailments, such as glaucoma by slowing down or preventing further optic nerve damage. For instance, in July 2025, according to GOV.UK, U.K-based government agency reported that, in financial year ending 2024, there were almost 3.7 million people who attended hospital outpatient appointments for vision in England, a rate of 6,127 (6,121 to 6,134) per 100,000 population. Therefore, the increase in the prevalence of eye disorders is driving the growth of the optic nerve disorder treatment market.

Key Players In The Global Optic Nerve Disorders Treatment Market

Major companies operating in the optic nerve disorders treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Sun Pharmaceutical Industries Limited, Bausch + Lomb Corporation, Horizon Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Allergan Inc., Akorn Inc., Ionis Pharmaceuticals Inc., Lumenis Ltd., Glaukos Corporation, Nidek Co. Ltd., Aerie Pharmaceuticals Inc., Spark Therapeutics Inc., IRIDEX Corporation, Kowa Company Limited, New World Medical Inc., Heidelberg Engineering GmbH, Editas Medicine Inc., Quark Pharmaceuticals Inc., iSTAR Medical SA, Neurotech Pharmaceuticals Inc., Nicox SA., GenSight Biologics S.A., Inotek Pharmaceuticals Co., Oculis Holding AG

Global Optic Nerve Disorders Treatment Market Trends and Insights

Major companies operating in the optic nerve disorder treatment market are introducing innovations such as generic suspensions to sustain their position in the market. Generic suspensions for optic nerve disorders typically include corticosteroids or other anti-inflammatory agents in liquid form, designed to reduce inflammation and manage symptoms in conditions such as optic neuritis or other optic nerve diseases. For instance, in October 2024, Lupin, an India-based pharmaceutical company, launched the first generic version of prednisolone cetate ophthalmic suspension. This launch marks a significant advancement in the treatment options available for patients suffering from optic nerve disorders. The generic version of Prednisolone Acetate Ophthalmic Suspension provides a more affordable alternative to its branded counterpart, making it accessible to a wider range of patients. This formulation is designed to reduce inflammation and treat various eye conditions, including those affecting the optic nerve.

What Are Latest Mergers And Acquisitions In The Optic Nerve Disorders Treatment Market?

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition is anticipated to further Amgen's goal of providing pioneering treatments for rare diseases and bolster its prominent portfolio in inflammation therapeutics. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company developing rare disease medicines such as neuromyelitis optica spectrum disorder (NMOSD).

Regional Outlook

North America was the largest region in the optic nerve disorders treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Optic Nerve Disorders Treatment Market?

The optic nerve disorders treatment market consists of revenues earned by entities through surgical interventions, plasma exchange therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The optic nerve disorders treatment market also includes sales of corticosteroids, antibiotics and vitamin supplements that are used in providing optic nerve disorders treatment services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Optic Nerve Disorders Treatment Market Report 2026?

The optic nerve disorders treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the optic nerve disorders treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.